Mer­ck and As­traZeneca get Lyn­parza OK in Chi­na for new in­di­ca­tion; BAR­DA ex­er­cis­es first op­tion with Mar­i­nus

As­traZeneca and Mer­ck’s Lyn­parza is ap­proved in Chi­na for yet an­oth­er in­di­ca­tion.

Chi­nese reg­u­la­tors ap­proved the block­buster can­cer drug and PARP in­hibitor as a first-line main­te­nance treat­ment for adults in sev­er­al spe­cif­ic cir­cum­stances: with ad­vanced ep­ithe­lial ovar­i­an, fal­lop­i­an tube or pri­ma­ry peri­toneal can­cer, who are in com­plete or par­tial re­sponse to first-line plat­inum-based chemother­a­py in com­bi­na­tion with Avastin, and whose can­cer is as­so­ci­at­ed with ho­mol­o­gous re­com­bi­na­tion de­fi­cien­cy (HRD)-pos­i­tive sta­tus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER